Drug Safety Update: Fezolinetant (Veoza)
The MHRA has issued new safety recommendations for fezolinetant (Veoza) following reports of drug-induced liver injury in patients receiving this treatment. Healthcare providers should be aware of this risk and implement appropriate monitoring protocols.
Key Points
- Fezolinetant treatment carries a documented risk of drug-induced liver injury
- New recommendations have been introduced to identify and minimise this risk
- Liver function monitoring is now mandatory before and during treatment in all patients
- Clinicians should review current patient management in light of these new guidelines
Affected Medication
- Fezolinetant (Veoza)
Recommended Actions
All healthcare providers prescribing or managing patients on fezolinetant should:
- Review the full MHRA safety alert for detailed monitoring recommendations
- Ensure baseline liver function tests are performed before initiating treatment
- Establish a schedule for ongoing liver function monitoring during therapy
- Discuss the risks and benefits with patients, particularly those with pre-existing liver disease
- Report any suspected adverse reactions via the Yellow Card scheme
Further Information
For the complete safety update and detailed clinical guidance, visit the MHRA Drug Safety Update page.